RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Survey unveils impact of gene regulation on human health

Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.

19 Mar 2010

Acne drug prevents HIV breakout

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

18 Mar 2010

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

Developments in nanotechnology and nanorobotics are opening up the prospects for nanomedicine and regenerative medicine where informatics and DNA computing can become the catalysts enabling health care applications at sub-molecular or atomic scales. While nanomedicine promises a new exciting frontier for clinical practice and biomedical research, issues involving cost-effectiveness studies, clinical trials and toxicity assays, drug delivery methods, and the implementation of new personalized therapies still remain challenging.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Using sophisticated techniques that scan the genomes of patients, researchers at the Mayo Clinic campus in Florida have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.

18 Mar 2010

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Balancing high-throughput sequencing and related bioinformatics analysis between a research group’s internal efforts and specialized service providers can both speed results to difficult biological questions and provide cost-effective access to the latest technology, says Eureka Genomics (EG). The company’s unique capabilities and services and how they can help in “Finding the Right Balance” will be the topic of discussion at a “Java and Jive” session on Wednesday March 17, 8:15 am at the Now-Generation Sequencing conference being held at the Hilton San Diego Resort in San Diego, CA.

17 Mar 2010

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Agilent Technologies Inc. today announced the availability of new ion exchange and size exclusion columns specifically designed for the analysis of bio-molecules including monoclonal antibodies, recombinant proteins, peptides, vaccine products and DNA/RNA. The columns provide robust, reproducible and high-resolution solutions for biopharmaceutical manufacturers to effectively monitor the safety, efficacy and stability of their products.

17 Mar 2010

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.

17 Mar 2010

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

16 Mar 2010

Regado Biosciences announces first successful subcutaneous application of an aptamer

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.

15 Mar 2010

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

Hemispherx Biopharma, Inc., announced its financial results for the fiscal year ended December 31, 2009. The net loss for the year (including non-cash charges) was approximately $13,438,000 or $0.12 per share as compared to a net loss of $12,219,000 or $0.16 per share in 2008.

15 Mar 2010

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new pre-clinical data from its hypercholesterolemia program, performed in collaboration with scientists at the University of Texas Southwestern Medical Center at Dallas. The data were presented at the PCSK9 Conference: From Gene to Therapeutics held in Nantes, France from March 11-13, 2010.

15 Mar 2010

Discovery of novel cellular mechanism may help develop new treatments for cancer

A research team led by the University of Colorado at Boulder has discovered a previously unknown cellular "switch" that may provide researchers with a new means of triggering programmed cell death, findings with implications for treating cancer.

12 Mar 2010

Microchip Biotechnologies renamed as IntegenX

Microchip Biotechnologies, a maker of automated microscale biotech laboratory systems, today announced that it has changed its business name to IntegenX. The new name articulates the company's focus on integrating sample preparation and analysis technologies into complete products that address generic problems shared by life science and biotechnology research laboratories worldwide.

12 Mar 2010

Octenol compound aids mosquitoes in finding blood meal

The potentially deadly yellow-fever-transmitting Aedes aegypti mosquito detects the specific chemical structure of a compound called octenol as one way to find a mammalian host for a blood meal, Agricultural Research Service (ARS) scientists report.

11 Mar 2010

Molecular master switch plays a key role in maturation process of brain cells

About four out of every 10 cells in the brain are so-called oligodendrocytes. These cells produce the all-important myelin that coats nerve tracts, ensuring fast, energy-efficient transmission of nerve impulses.

11 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

What began as research into how diabetics could possibly preserve their eyesight has led to findings that could prolong the vision of children afflicted with retinoblastoma.

10 Mar 2010

Genta announces private placement of Convertible Notes for $25M

Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.

8 Mar 2010

RNA News and Research

Further Reading

Survey unveils impact of gene regulation on human health

Acne drug prevents HIV breakout

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Regado Biosciences announces first successful subcutaneous application of an aptamer

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Discovery of novel cellular mechanism may help develop new treatments for cancer

Microchip Biotechnologies renamed as IntegenX

Octenol compound aids mosquitoes in finding blood meal

Molecular master switch plays a key role in maturation process of brain cells

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

Genta announces private placement of Convertible Notes for $25M

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo